Market Place
Sourcing Support
UCB Presents Data On Epilepsy At AES 2024 Annual Meeting
06 Dec 2024 //
PR NEWSWIRE
CBC Group Complete Strategic Acquisition Of UCB’s Product Portfolio
29 Nov 2024 //
PR NEWSWIRE
UCB Presents Epilepsy Research at AES Annual Meeting
26 Nov 2024 //
PR NEWSWIRE
UCB receives FDA approval for BIMZELX For hidradenitis suppurativa
21 Nov 2024 //
PRESS RELEASE
Dapirolizumab Pegol Ph 3 Data Shows Lupus Disease Activity Reduction
19 Nov 2024 //
GLOBENEWSWIRE
Roche tosses out $120M tau prospect, returning rights to UCB
23 Oct 2024 //
FIERCE BIOTECH
UCB`s Biologic Bimzelx (Bimekizumab) Receives Suppl. Approval in US
11 Oct 2024 //
FDA
UCB blockbuster potential for Bimzelx with 3 new FDA approvals "
24 Sep 2024 //
FIERCE PHARMA
Biogen-UCB`s lupus drug meets main goal of late-stage trial
24 Sep 2024 //
PRESS RELEASE
UCB`s Biologic Bimzelx (Bimekizumab) Receives Suppl Approval in US
20 Sep 2024 //
FDA
Argenx isn`t sweating over Vyvgart competitors: exec
10 May 2024 //
FIERCE PHARMA
UCB: Neurology Developments At AAN 2024
12 Apr 2024 //
PR NEWSWIRE
FDA Accepts sBLA for BIMZELX for Moderate-to-Severe Hidradenitis Suppurativa
04 Apr 2024 //
PR NEWSWIRE
UCB debuts first campaign for psoriasis drug Bimzelx during Oscars
12 Mar 2024 //
ENDPTS
PANTHERx® Rare Selected by UCB as the Exclusive Specialty Pharmacy for ZILBRYSQ
10 Jan 2024 //
PR NEWSWIRE
UCB departs industry trade group BIO, following Pfizer`s exit late last year
04 Jan 2024 //
ENDPTS
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S
03 Jan 2024 //
PR NEWSWIRE
UCB presents new data about the real-world experience of FINTEPLA
02 Dec 2023 //
PR NEWSWIRE
UCB Announces U.S. Availability of BIMZELX® for Plaque Psoriasis
14 Nov 2023 //
PR NEWSWIRE
Post Hoc Analysis Showed CIMZIA Resulted in Meaningful Efficacy for RA Patients
11 Nov 2023 //
PR NEWSWIRE
UCB Presents New Five-Year Data on BIMZELX in Ankylosing Spondylitis
10 Nov 2023 //
PR NEWSWIRE
UCB`s Biologic Cimzia (certolizumab pegol) Receives Approval in the U.S.
08 Nov 2023 //
FDA
UCB presents latest data from generalized myasthenia gravis portfolio
01 Nov 2023 //
PR NEWSWIRE
NAYZILAM Results Published in `Epilepsy & Behavior`
31 Oct 2023 //
PR NEWSWIRE
UCB wins FDA approvals in plaque psoriasis and gMG
19 Oct 2023 //
ENDPTS
UCB announces U.S. FDA approval of ZILBRYSQ for myasthenia gravis
17 Oct 2023 //
PR NEWSWIRE
UCB`s Biologic Bimzelx (bimekizumab) Receives Approval in the U.S.
17 Oct 2023 //
FDA
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa
13 Oct 2023 //
PR NEWSWIRE
Phase 3 Data Presented at EADV 2023 Showed Bimekizumab Achieved Thresholds
12 Oct 2023 //
PR NEWSWIRE
UCB announces U.S. availability of RYSTIGGO for the treatment of gMG
21 Jul 2023 //
PR NEWSWIRE
FDA signs off on UCB`s myasthenia gravis drug Rystiggo
28 Jun 2023 //
FIERCE PHARMA
Belgium`s UCB hit with FDA Form 483 after April inspection
31 May 2023 //
FIERCE PHARMA
FDA Issues form 483 to UCB Pharma SA
25 May 2023 //
FDA
Veeva, UCB link to leverage digital tools in clinical trials
24 May 2023 //
FIERCE BIOTECH
UCB and Ariceum sign a Strategic Research Collab to Discover New Modalities
10 May 2023 //
PR NEWSWIRE
Huma and UCB partner to provide digital health solution to improve rare disease
26 Apr 2023 //
PR NEWSWIRE
UCB Showcases Strength and Depth of Neurology Portfolio at 75th (AAN) Meeting
20 Apr 2023 //
PR NEWSWIRE
UCB`s second shot at Neupro patent validation fails on appeal
13 Apr 2023 //
FIERCE PHARMA
Novartis, UCB set to battle it out in inflammatory skin disease
10 Apr 2023 //
FIERCE PHARMA
Bimekizumab PIII Data in Hidradenitis Suppurativa Shows Response over 48 Weeks
18 Mar 2023 //
PR NEWSWIRE
UCB to Present Eight Bimekizumab Abstracts at AAD 2023
16 Mar 2023 //
PR NEWSWIRE
UCB, Aitia Enter Strategic Drug Discovery Alliance in Huntington`s Disease
16 Mar 2023 //
CONTRACT PHARMA
Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab PIII
18 Jan 2023 //
PR NEWSWIRE
UCB`s bimekizumab granted FDA 6-month review period
29 Dec 2022 //
FIERCE PHARMA
UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab
23 Dec 2022 //
PIPELINEREVIEW
UCB`s Biologic Cimzia (Certolizumab Pegol) Receives Approval in the U.S.
22 Dec 2022 //
FDA
Praxis ends year on high with $100M biobucks UCB deal
15 Dec 2022 //
FIERCEBIOTECH
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
13 Dec 2022 //
GLOBENEWSWIRE
UCB`s psoriasis drug proves itself in hidradenitis suppurativa
10 Dec 2022 //
FIERCEPHARMA
UCB`s Vimpat Receives Approval in Europe
08 Dec 2022 //
EMA
The Lancet Publishes Results from Bimekizumab PIII Study in Psoriatic Arthritis
07 Dec 2022 //
PRNEWSWIRE
UCB presents latest data from generalized myasthenia gravis portfolio
22 Sep 2022 //
UCB
EMA ccepts Marketing Authorization Applications for Bimekizumab
20 Sep 2022 //
PHARMIWEB
China suspends UCB`s anti-seizure drug Keppra after manufacturing issue
25 Aug 2022 //
FIERCEPHARMA
UCB pens multiple collabs to boost cluster seizure awareness
23 Aug 2022 //
FIERCEPHARMA
UCB lowers 2022 profit expectations amid rising costs
24 Jun 2022 //
FIERCEPHARMA
Positive MHRA decision for Briviact
23 Jun 2022 //
PHARMATIMES
Roswell Biotechnologies Forges Early Research Collaboration with UCB
08 Jun 2022 //
PRNEWSWIRE
NICE recommends UCB’s Fintepla for Dravet syndrome
01 Jun 2022 //
PHARMATIMES
Purchase of UCB shares
23 May 2022 //
GLOBENEWSWIRE
